首頁 > 市場調查報告書 > 醫療設備

導管醫學影像診斷 CT/MRI/X光分子呈像/呈影劑

市場調查報告書

商品編碼

1576946

Angiosuite - 市場考察，競爭情形，市場預測(～2030年)

Angio Suites - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 2024年10月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

2023 年，全球 Angiosuite 市場規模為 21.8 億美元，預計到 2030 年將達到 30.5 億美元，2024-2030 年預測期間複合年增長率為 5.75%。該市場的主要推動因素包括心房顫動、週邊動脈疾病（PAD）和冠狀動脈疾病（CAD）等心血管疾病等慢性病患者數量的增加、主要參與者的創新產品開發活動以及老年人口的增加預計在2024年至2030 年預測期內，整個Angiosuite 市場將加速成長。

Angiosuite 市場動態

根據《世界心臟報告（2023）》提供的數據，2021年全球將有超過5億人罹患心血管疾病。此外，根據美國心臟協會（2023）最新提供的數據，預計到2030年，全球將有超過1,200萬人受到心房顫動的影響。

根據英國心臟基金會的《全球心臟和循環系統疾病情況說明書》（2024 年），全球約有 2 億人患有 CAD。

根據美國心臟協會 (2023) 的數據，全球平均約有 2 億人患有 PAD。此外，根據《全球疾病負擔》（2019），2019年全球40至70歲的周邊動脈疾病患者人數為5,640萬人。

Angiosuites 對於 CAD、PAD 和心房顫動等心血管疾病的診斷和治療至關重要。此外，AngioSuite 可用於基於導管的手術，例如心房顫動消融術以恢復正常心律。

推動 Angiosuites 市場成長的另一個主要因素是產品設計的持續技術發展，以提高 Angiosuites 市場的安全性和準確性。例如，2021年10月，印度塞康德拉巴德的雅紹達醫院推出了DTAS（Direct to Angio Suite）技術，用於在中風和心臟病等神經系統緊急情況下提供快速和先進的治療）技術。， "雙平面神經血管手術套件" 。

世界各地監管機構增加的產品開發活動預計也將推動 angiosuite 的市場成長。例如，2022 年 5 月，飛利浦宣布其新型 MR 7700 3.0T MR 系統獲得 FDA 510(k) 許可。

因此，上述所有因素共同推動了整個 Angiosuites 市場的成長。

然而，感染、血腫和血管損傷等副作用、缺乏熟練勞動力和醫療基礎設施可能會對血管甜味劑市場的成長帶來課題。

Angiosuites 細分市場分析

在 Angiosuite 市場的應用領域，支架類別預計將在 2023 年佔據重要的收入佔有率。這是由於世界各地急性中風病例所需的支架置入手術數量不斷增加，以及全球中風盛行率不斷上升，這與殘疾和死亡等嚴重後果有關，Angiosuite 市場的這一領域預計將產生巨大的影響。

此外，穿戴式血管套件開發過程中發生的技術進步和產品創新可能會推動血管套件市場的成長。例如，2022年6月，西門子Healthineers推出了血管攝影系統Artis Icono，適用於支架置入、中風診斷和治療等多種應用。該系統採用新的系統架構和 2D 和 3D 成像的影像鏈，具有無縫整合和第三方介面。

本報告提供全球Angiosuite市場相關調查分析，提供各地區市場規模與預測，過去3年的產品/技術開發，市場主要企業，未來的機會等資訊。

Siemens Healthineers
Koninklijke Philips N.V
Lam Vascular and Associates
Hitachi, Ltd.
ESAOTE SPA
IMRIS
Onex Corporation
Canon Inc.
3D Systems, Inc.
GE HealthCare
Shimadzu Corporation
GIMIAS
FUJIFILM Holdings Corporation
Hologic, Inc.
Planmeca
Mindray Medical International Limited
ZEISS International
Guerbet
Surgical Science
B.Braun Melsungen AG

第9章 KOL的見解

第10章計劃的方法

第11章關於DelveInsight

第12章免責聲明，諮詢方式

簡介目錄圖表

Product Code: DIMDCL0329

Angio Suites Market by Type (Single-Plane and Bi-Plane), Application (Angiography, Angioplasty, Stenting, Bypass Surgery, and Others), and Geography (North-America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing cases of chronic disorders and the rising product developmental activities worldwide

The angio suites market was valued at USD 2.18 billion in 2023, growing at a CAGR of 5.75% during the forecast period from 2024 to 2030 to reach USD 3.05 billion by 2030. The angio suites market is observing substantial market growth primarily owing to the increasing cases of chronic disorders such as cardiovascular diseases including atrial fibrillation, peripheral artery disease (PAD), and coronary artery disease (CAD), innovative product developmental activities by leading companies, and the rising geriatric population that are expected to escalate the overall growth of the angio suites market during the forecast period from 2024 to 2030.

Angio Suites Market Dynamics:

As per data provided by the World Heart Report (2023), in 2021 it was stated that more than half a billion people were living with cardiovascular diseases globally. Further, according to recent data provided by the American Heart Association (2023), it is estimated that by 2030 over 12 million people will have atrial fibrillation globally.

According to British Heart Foundation, Global Heart & Circulatory Diseases Factsheet (2024), it stated that around 200 million people are living with CAD around the world.

As per data by the American Heart Association (2023), around 200 million live with PAD globally on average. Also, as per the Global Burden of Disease (2019), there were 56.4 million prevalent cases of PAD among those aged 40 to 70, worldwide in 2019.

Angio suites are vital for diagnosing and treating cardiovascular diseases like CAD, PAD, and atrial fibrillation. Moreover, angio suites can be used for catheter-based procedures like atrial fibrillation ablation to restore normal heart rhythm.

Another prominent factor responsible for the growth of the angio suites market is the constant technological developments taking place in the angio suites market for product design, and for increasing its safety and precision. For instance, in October 2021, Yashoda Hospitals, located in Secunderabad, India launched a 'Bi-Plane Neuro Angio Procedure Suite' with DTAS (Direct to Angio Suite) technology used for providing quick and highly advanced treatment in cases of brain stroke and neurological emergencies such as heart attacks.

Increased product developmental activities by regulatory bodies worldwide is also slated to witness market growth for angio suites. For example in May 2022, Philips announced FDA 510(k) clearance for its new MR 7700 3.0T MR system, giving high performance and precision for both research and advanced clinical diagnostics.

Therefore, all the factors stated above collectively will drive the overall angio suites market growth.

However, side effects such as infections, hematoma, vessel injuries, lack of skilled workforce and medical infrastructure, and others may prove to be challenging factors for the angio suites market growth.

Angio Suites Market Segment Analysis:

In the application segment of angio suites market, the stenting category is expected to have a significant revenue share in the year 2023. This can be ascribed to an increase in stenting procedures around the world, required in acute cases of stroke, rising prevalence of stroke cases globally, leading to serious consequences like disability and death, this segment of the angio suites market is expected to generate considerable revenue.

Furthermore, technological advancements and product innovations taking place in the development of wearable angio suites are likely to propel the angio suites market growth. For instance, in June 2022, Siemens Healthineers, launched the Angiography System Artis Icono, for various applications like stenting, stroke diagnosis and treatment and others. It is enabled with new system mechanics and image chains for 2D and 3D imaging with seamless integration and a third-party interface.

Angio suites designed for stenting procedures feature advanced imaging technologies, specialized catheterization tools, and patient monitoring systems. They are primarily used to treat CAD and PAD by placing stents to keep narrowed or blocked arteries open, thus improving blood flow and reducing the risk of heart attacks. These suites also facilitate emergency interventions for acute coronary syndromes, ensuring timely cardiovascular care.

Therefore, the widespread uses and various key features offered by stenting category, that enhance performance and usability are solidifying the impact on the growth of the overall angio suites market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall angio suites market:

Among all the regions, North America is expected to dominate the angio suites market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high prevalence of CAD and other heart conditions, along with associated risk factors for cardiovascular disorders, combined with significant advancements in product development and regulatory approvals that are acting as key factors contributing to the growth of the angio suites market in the North America region during the forecast period from 2024 to 2030.

As per data provided by the National Institute of Health (2023), it stated that 20.5 million people in the US were living with CAD. Furthermore, according to data from the Centers for Disease Control and Prevention (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications such as acute coronary syndrome, atherosclerosis, and congestive heart failure among others.

Data from the Canadian Institute for Health Information (2024), stated that in 2022, 2.4 million Canadians were affected by heart disease. Also, according to the American Health Association (2022), Canada stands the second most to be affected by stroke globally in the year 2021.

Angio suites enable crucial diagnostic procedures like angiography to visualize coronary arteries and identify blockages. For myocardial infarction, angio suites facilitate interventions such as angioplasty and stenting to restore blood flow to the heart. Their versatility also allows for the treatment of various heart conditions, ensuring timely diagnosis and effective care.

Rising product developmental activities by regulatory bodies in the region will further boost the market for angio suites. For example, in March 2022, Philips received 510(k) market clearance from the U.S. Food & Drug Administration (FDA) for its angio suite Philips Capsule Surveillance solution, paving the way for widespread deployment across healthcare systems in the US. The angio suite is capable of utilizing streaming data from virtually any connected medical device and helps in the analysis to generate actionable insights and alerts.

Additionally, in June 2022, Canon Medical Systems decided to collaborate with The Harley Street Healthcare Group Canada to launch a group of innovative diagnostic centers across Ontario. The diagnostic center is said to possess a highly equipped Angiography suite with the latest X-ray generators, Molecular Imaging, Ultrasound, and Healthcare Informatics.

Therefore, the presence of a large patient population base with heart disorders, coupled with a rise in regulatory approvals for angio suites is expected to bolster the growth of the angio suites market in the North American region during the forecast period.

Angio Suites Market key players:

Some of the key market players operating in the angio suites market include Siemens Healthineers, Koninklijke Philips N.V, Lam Vascular and Associates, Hitachi, Ltd., ESAOTE SPA, IMRIS, Onex Corporation, Canon Inc., 3D Systems, Inc., GE HealthCare, Shimadzu Corporation, GIMIAS, FUJIFILM Holdings Corporation, Hologic, Inc., Planmeca, Mindray Medical International Limited, ZEISS International, Guerbet, Surgical Science, B.Braun Melsungen AG, and others.

Recent Developmental Activities in the Angio Suites Market:

In June 2022, Siemens Healthineers, launched the Angiography System Artis Icono, for precise tumor embolization. It is enabled with new system mechanics and image chains for 2D and 3D imaging with seamless integration and a third-party interface.
In December 2021, GE Healthcare, an auxiliary company of well-known Massachusetts, United States-based company "General Electric" announced the successful acquisition of Boston, United States-based imaging company "BK Medical".

Key Takeaways from the Angio Suites Market Report Study

Market size analysis for current angio suites market size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the angio suites market.
Various opportunities available for the other competitors in the angio suites market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current angio suites market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for automated external defibrillator market growth in the coming future?

Target Audience who can be benefited from this Angio Suites Market Report Study

Angio suites product providers
Research organizations and consulting companies
Angio suites-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in angio suites
Various end-users who want to know more about the angio suites market and the latest technological developments in the angio suites market.

Frequently Asked Questions for the Angio Suites Market:

1. What are angio suites?

The angio suite is an examination room where complex surgical procedures like angiography, stenting, bypass surgery, etc. are performed with high precision. It helps in the detection and observation of damaged blood vessels present in different organs, helping in the diagnosis and treatment of conditions like aneurysms, vascular stenosis, coronary atherosclerosis, etc.

2. What is the market for angio suites?

The angio suites market was valued at USD 2.18 billion in 2023, growing at a CAGR of 5.75% during the forecast period from 2024 to 2030 to reach USD 3.05 billion by 2030.

3. What are the drivers for the angio suites market?

The angio suites market is observing substantial market growth primarily owing to the increasing cases of chronic disorders such as cardiovascular diseases including atrial fibrillation, peripheral artery disease (PAD), and coronary artery disease (CAD), innovative product developmental activities by leading companies, and the rising geriatric population that are expected to escalate the overall growth of the angio suites market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the angio suites market?

Some of the key market players operating in the angio suites market include Siemens Healthineers, Koninklijke Philips N.V, Lam Vascular and Associates, Hitachi, Ltd., ESAOTE SPA, IMRIS, Onex Corporation, Canon Inc., 3D Systems, Inc., GE HealthCare, Shimadzu Corporation, GIMIAS, FUJIFILM Holdings Corporation, Hologic, Inc., Planmeca, Mindray Medical International Limited, ZEISS International, Guerbet, Surgical Science, B.Braun Melsungen AG, and others.

5. Which region has the highest share in the angio suites market?

North America is expected to dominate the overall angio suites market during the forecast period from 2024 to 2030. This can be attributed to several factors including the high prevalence of coronary artery disease and other heart conditions, along with associated risk factors for cardiovascular disorders, combined with significant advancements in product development and regulatory approvals that are acting as key factors contributing to the growth of the angio suites market in the North America region during the forecast period from 2024 to 2030.

1. Angio Suites Market Report Introduction

1.1. Scope of the Study
1.2. Market Segmentation
1.3. Market Assumption

2. Angio Suites Market Executive Summary

2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

4.1. The United States
4.2. Europe
4.3. Japan
4.4. China

5. Angio Suites Market Key Factors Analysis

5.1. Angio Suites Market Drivers
- 5.1.1. Increasing cases of chronic disorders
- 5.1.2. Rising product developmental activities
- 5.1.3. Rising geriatric population
5.2. Angio Suites Market Restraints and Challenges
- 5.2.1. Side effects such as infections, hematoma, and vessel injuries
- 5.2.2. Lack of skilled workforce and medical infrastructure
5.3. Angio Suites Market Opportunities
- 5.3.1. Integration of AI, robotics and automation
- 5.3.2. Increasing regulatory and research opportunities

6. Angio Suites Market Porter's Five Forces Analysis

6.1. Bargaining Power of Suppliers
6.2. Bargaining Power of Consumers
6.3. Threat of New Entrants
6.4. Threat of Substitutes
6.5. Competitive Rivalry

7. Angio Suites Market Assessment

7.1. By Type
- 7.1.1. Single-plane
- 7.1.2. Bi-plane
7.2. By Application
- 7.2.1. Angiography
- 7.2.2. Angioplasty
- 7.2.3. Stenting
- 7.2.4. Bypass Surgery
- 7.2.5. Others
7.3. By Geography
- 7.3.1. North America
  - 7.3.1.1. United States Angio Suites Market Size in USD million (2021-2030)
  - 7.3.1.2. Canada Angio Suites Market Size in USD million (2021-2030)
  - 7.3.1.3. Mexico Angio Suites Market Size in USD million (2021-2030)
- 7.3.2. Europe
  - 7.3.2.1. France Angio Suites Market Size in USD million (2021-2030)
  - 7.3.2.2. Germany Angio Suites Market Size in USD million (2021-2030)
  - 7.3.2.3. United Kingdom Angio Suites Market Size in USD million (2021-2030)
  - 7.3.2.4. Italy Angio Suites Market Size in USD million (2021-2030)
  - 7.3.2.5. Spain Angio Suites Market Size in USD million (2021-2030)
  - 7.3.2.6. Rest of Europe Angio Suites Market Size in USD million (2021-2030)
- 7.3.3. Asia-Pacific
  - 7.3.3.1. China Angio Suites Market Size in USD million (2021-2030)
  - 7.3.3.2. Japan Angio Suites Market Size in USD million (2021-2030)
  - 7.3.3.3. India Angio Suites Market Size in USD million (2021-2030)
  - 7.3.3.4. Australia Angio Suites Market Size in USD million (2021-2030)
  - 7.3.3.5. South Korea Angio Suites Market Size in USD million (2021-2030)
  - 7.3.3.6. Rest of Asia-Pacific Angio Suites Market Size in USD million (2021-2030)
- 7.3.4. Rest of the World (RoW)
  - 7.3.4.1. Middle East Angio Suites Market Size in USD million (2021-2030)
  - 7.3.4.2. Africa Angio Suites Market Size in USD million (2021-2030)
  - 7.3.4.3. South America Angio Suites Market Size in USD million (2021-2030)

8. Angio Suites Market Company and Product Profiles

8.1. Siemens Healthineers
- 8.1.1. Company Overview
- 8.1.2. Company Snapshot
- 8.1.3. Financial Overview
- 8.1.4. Product Listing
- 8.1.5. Entropy
8.2. Koninklijke Philips N.V
- 8.2.1. Company Overview
- 8.2.2. Company Snapshot
- 8.2.3. Financial Overview
- 8.2.4. Product Listing
- 8.2.5. Entropy
8.3. Lam Vascular and Associates
- 8.3.1. Company Overview
- 8.3.2. Company Snapshot
- 8.3.3. Financial Overview
- 8.3.4. Product Listing
- 8.3.5. Entropy
8.4. Hitachi, Ltd.
- 8.4.1. Company Overview
- 8.4.2. Company Snapshot
- 8.4.3. Financial Overview
- 8.4.4. Product Listing
- 8.4.5. Entropy
8.5. ESAOTE SPA
- 8.5.1. Company Overview
- 8.5.2. Company Snapshot
- 8.5.3. Financial Overview
- 8.5.4. Product Listing
- 8.5.5. Entropy
8.6. IMRIS
- 8.6.1. Company Overview
- 8.6.2. Company Snapshot
- 8.6.3. Financial Overview
- 8.6.4. Product Listing
- 8.6.5. Entropy
8.7. Onex Corporation
- 8.7.1. Company Overview
- 8.7.2. Company Snapshot
- 8.7.3. Financial Overview
- 8.7.4. Product Listing
- 8.7.5. Entropy
8.8. Canon Inc.
- 8.8.1. Company Overview
- 8.8.2. Company Snapshot
- 8.8.3. Financial Overview
- 8.8.4. Product Listing
- 8.8.5. Entropy
8.9. 3D Systems, Inc.
- 8.9.1. Company Overview
- 8.9.2. Company Snapshot
- 8.9.3. Financial Overview
- 8.9.4. Product Listing
- 8.9.5. Entropy
8.10. GE HealthCare
- 8.10.1. Company Overview
- 8.10.2. Company Snapshot
- 8.10.3. Financial Overview
- 8.10.4. Product Listing
- 8.10.5. Entropy
8.11. Shimadzu Corporation
- 8.11.1. Company Overview
- 8.11.2. Company Snapshot
- 8.11.3. Financial Overview
- 8.11.4. Product Listing
- 8.11.5. Entropy
8.12. GIMIAS
- 8.12.1. Company Overview
- 8.12.2. Company Snapshot
- 8.12.3. Financial Overview
- 8.12.4. Product Listing
- 8.12.5. Entropy
8.13. FUJIFILM Holdings Corporation
- 8.13.1. Company Overview
- 8.13.2. Company Snapshot
- 8.13.3. Financial Overview
- 8.13.4. Product Listing
- 8.13.5. Entropy
8.14. Hologic, Inc.
- 8.14.1. Company Overview
- 8.14.2. Company Snapshot
- 8.14.3. Financial Overview
- 8.14.4. Product Listing
- 8.14.5. Entropy
8.15. Planmeca
- 8.15.1. Company Overview
- 8.15.2. Company Snapshot
- 8.15.3. Financial Overview
- 8.15.4. Product Listing
- 8.15.5. Entropy
8.16. Mindray Medical International Limited
- 8.16.1. Company Overview
- 8.16.2. Company Snapshot
- 8.16.3. Financial Overview
- 8.16.4. Product Listing
- 8.16.5. Entropy
8.17. ZEISS International
- 8.17.1. Company Overview
- 8.17.2. Company Snapshot
- 8.17.3. Financial Overview
- 8.17.4. Product Listing
- 8.17.5. Entropy
8.18. Guerbet
- 8.18.1. Company Overview
- 8.18.2. Company Snapshot
- 8.18.3. Financial Overview
- 8.18.4. Product Listing
- 8.18.5. Entropy
8.19. Surgical Science
- 8.19.1. Company Overview
- 8.19.2. Company Snapshot
- 8.19.3. Financial Overview
- 8.19.4. Product Listing
- 8.19.5. Entropy
8.20. B.Braun Melsungen AG
- 8.20.1. Company Overview
- 8.20.2. Company Snapshot
- 8.20.3. Financial Overview
- 8.20.4. Product Listing
- 8.20.5. Entropy